Cover Page

BARI-STEP: A double-blinded, randomised, placebo-controlled trial of semaglutide 2.4 mg in patients with poor weight-loss following bariatric surgery.

NCT05073835

Document: PIS-ICF
Version: 4.1; 24-10-2023

Participant Information Sheet

Sponsor Protocol Number: 142522
IRAS ID number: 299128

Study Title: BARI-STEP Trial: A double-blinded, randomised, placebo-controlled trial of semaglutide 2.4 mg in patients with poor weight-loss following bariatric surgery.

University College London (the Sponsor of the study) would like to invite you to take part in a clinical trial looking at how well a drug called semaglutide works in lowering body weight and improving health in people with poor weight loss following bariatric surgery. Before you decide if you would like to take part, it is important that you understand why this study is being done and what it will involve for you. This participant information sheet explains the study and what will happen if you decide to take part. Please take your time to read this information carefully. A member of our study team will go through this information with you and answer any questions you may have. You may also wish to discuss this information with your GP, your family or friends before deciding if you would like to take part.

Part 1 - *What is involved in the Research Study?*
Tells you the purpose of this study and what will happen to you if you take part.

Part 2 – *Supporting Information*
Gives you more detailed information about the conduct of the study.

Ask us if there is anything that is not clear. Take time to decide whether or not you wish to take part. We appreciate it may not answer all of your questions, so please do not hesitate to contact a member of the study team on the telephone numbers given at the end of this Information Sheet if you would like to discuss any aspect of the study further.

Thank you for taking the time to read this information.

Important things you need to know before reading:

Overview of the trial

You have been invited to take part in the BARI-STEP trial because you had bariatric surgery one year ago, or more, and despite this, your weight loss is not considered optimal. Drug treatments are increasingly becoming available for weight management however, it is not yet known how effective these will be in people who have had bariatric surgery. The BARI-STEP trial will test one of these drugs, called semaglutide, in people who have had bariatric surgery and we think you might be eligible to participate in this study.

The BARI-STEP trial is a double blind, randomised, placebo-controlled trial. This means that if you take part in the trial, you will receive ***either*** the study drug being tested (semaglutide) ***OR*** a placebo.

The placebo looks identical in every way to the study drug, however it does not contain any active substance. Placeboes are used as a control to measure the effectiveness of the study drug (semaglutide). Those receiving placebo do not experience the effects of the study drug and their treatment is used as a comparison to the effects of the study drug treatment.

As this is a randomised trial, you will be allocated a treatment group (either semaglutide or placebo) at random. Neither you nor the research team will be aware of which treatment you have been allocated. This is called a double blind.

This is a summary of what taking part in the trial will involve:

- The trial will look at the change in your body weight, your body fat percentage and your quality of life ratings from the start to the end of the trial.
- The trial will compare the how well semaglutide works compared to placebo (a 'dummy' medicine) in aiding weight loss after bariatric surgery, over a 68 week treatment period.
- You will receive either semaglutide OR placebo – which treatment you get will be decided by chance and at random.
- You will need to take an injection of either semaglutide or placebo once a week, on the same day of the week.
- In addition to the injections, you will be talking to the healthcare professionals from our team about nutrition, lifestyle, physical activity and your health.
- You will have 7 clinic visits and 19 remote visits with our trial team.
- You will complete some questionnaires during the site visits.
- At 7 of the visits you will have blood samples taken.
- We will ask you to fast overnight before one of the visits.
- The trial will last for approximately 1 ½ years.

Are there people who cannot take semaglutide or take part in the trial?

For safety reasons, pregnant and breast-feeding women and people with certain underlying medical conditions will not be able to take part. You may not be eligible to participate if you have certain medical conditions (including significant kidney, heart or liver disease, type 1 diabetes or type 2 diabetes treated with insulin or pancreatitis). Your medical history will be checked to see if there is any reason why you cannot take part in the trial. Potentially eligible participants will be invited to attend a screening visit during which their suitability to take part in the study will be assessed against a list of criteria. If any of these criteria are not met, enrolment into the study will not be allowed. The outcome of this screening will be shared and fully explained to you once all screening data is collected and reviewed by a qualified member of the research team.

This participant information sheet will provide further information about the trial and what is involved in more detail.

Part 1 - What is involved in the Research Study?

1. What is the purpose of the study?

Weight loss surgery, also called bariatric surgery, is currently the most effective treatment for people living with severe obesity. Bariatric surgery reduces body fat and improves health and life expectancy in people living with severe obesity and related complications (such as high blood pressure and type 2 diabetes). Bariatric surgery changes a person's appetite and the foods they choose to eat, leading to consuming fewer foods that are high in calories. After bariatric surgery, the levels of hormones that control eating, appetite and body weight (known as gut hormones) change. These hormonal changes are likely to cause the change in appetite and food preference after surgery and contribute to weight loss. However, not every person loses the same amount of weight after bariatric surgery.

On average bariatric surgery leads to 25-30% weight loss. However, the amount of weight people lose after bariatric surgery is highly variable and some people experience suboptimal weight loss. A person is said to experience poor weight loss after bariatric surgery if they lose less than 20% of their original body weight at one year, or more, from the date of their surgery. The reasons why some people lose less weight after surgery are still not fully understood but it is thought that differences in the levels of gut hormones contribute to the differences in weight loss after surgery. One of these hormones, GLP-1, reduces appetite and lowers blood glucose (sugar) levels. Previous research studies have shown low levels of GLP-1 in people with poor weight loss after bariatric surgery.

Drugs based on GLP-1 have been used for several years to treat people with type 2 diabetes and one of those drugs based on GLP-1 (liraglutide, a daily injection) is approved for weight management in adults with obesity. Liraglutide has been shown to lead to greater weight loss than placebo in people who are overweight or living with obesity, as well as improvements in overall physical and mental health and quality of life. Liraglutide has been used in people with poor weight loss following bariatric surgery and was shown to be effective in lowering body weight. Semaglutide is a newer drug based on GLP-1, taken by a once weekly injection, which was shown to significantly lower body weight in people living with overweight or obesity and leads to greater weight loss than liraglutide. The purpose of this clinical trial is to compare the effects of 68-weeks of treatment with semaglutide 2.4mg on body weight, body fat percentage and quality of life in people with poor weight loss more than a year after bariatric surgery (gastric bypass or sleeve gastrectomy).

2. Why have I been invited?

You have been invited because you had either a gastric bypass or sleeve gastrectomy one year ago or more and based on your current weight you have lost less than 20% of your body weight from the day of your surgery, for which a surgical cause for poor weight loss has been ruled out.

3. Do I have to take part?

It is up to you to decide to join the study. We will describe the study and go through this information sheet. If you agree to take part, we will then ask you to sign a consent form. You are free to

withdraw at any time without giving a reason. This would not affect the standard of care you receive.

4. What will happen to me if I decide to take part?

If you decide to take part, you will be asked to sign two copies of the trial's consent form. You will be given a copy to take home and keep. An appointment at a day and time convenient for you will be arranged for you to attend for a screening visit. Signing the consent form will however not automatically enrol you in the trial. Your eligibility to participate will depend on the data obtained during the screening visit. The research team will notify you on the outcome of this.

The screening assessment (Visit 1): The purpose of the screening assessments is to see if you are suitable to take part in the trial. This visit will last approximately one hour. You will meet the study team who will explain the assessments and answer any questions you may have.

- You will be asked about your medical history and any medications you take.
- You will undergo a physical examination that involves measurement of your blood pressure, heart rate, height and weight.
- You will have a blood test.
- If you are a female of child-bearing age you will have to provide a urine sample for a pregnancy test.

The research team will then review all the data obtained from this visit and, if you qualify, you will be offered to participate in this clinical trial.

Baseline assessment (Visit 2): After confirming that you are eligible to participate in the trial, an appointment will be booked for you to attend for the baseline assessment. The day before this visit you will have to follow the standard post-surgery diet that has been advised by your dietitian and to refrain from doing strenuous exercise and drinking alcohol. You will be asked to eat nothing after 9:00 pm the night before the visit and to drink only water. The visit will last for approximately 3 hours and the following will take place:

- You will undergo a physical examination that involves measurement of your blood pressure, heart rate, height and weight.
- If you are a female of childbearing age you will have to provide a blood sample for a pregnancy test.
- You will undertake a meal test to assess your levels of the hormone GLP-1. For this test, you can choose whether you would prefer a cannula (a thin plastic tube that is placed into a vein on one arm) or venepuncture (a standard blood test) to collect blood samples. While the cannula is being inserted or during venepuncture, you may feel a slight discomfort when the cannula is inserted and you will then be asked to relax for approximately 30 minutes. A fasting blood sample will be taken (an equivalent of two (2) teaspoons worth of blood). You will then be asked to drink a liquid meal over a 10-minute period. Then, another blood sample will be taken at 30 minutes after having the meal. A blood sample to measure your thyroid, kidney, liver function and markers of inflammation will also be taken at the same time.

- You will have a bioelectrical impedance analysis (BIA) scan. This is a non-invasive and painless procedure that requires you to step on the pads of a scale. A very low level and safe electrical signal will measure your body fat and muscle mass.
- You will undertake an ECG, which will take a tracing of your heart rhythm.
- You will be given 4 questionnaires to complete, which will contain questions about appetite, physical activity and quality of life.
- You will be trained on how to perform the treatment injections.
- You will be given advice on nutrition and exercise.
- You will be given:
    - A drug diary to record your intake of the treatment drug and any side effects that you experience while on the treatment. We will ask you to bring this diary on your next study visit.
    - A set of scales for you to monitor your weight at home.
    - The trial medicine, injection needles and a sharps bin.

The study intervention

The medicine and placebo will present in the form of an injection pen that uses a very fine needle to administer the drug under the skin in your stomach, thigh or upper arm. You will receive a "Directions For Use" manual with the injection pen and be given training on how to perform the injection. You will have to take the injection once every week on the same day of the week. You will also be advised to follow a specific diet and to increase your physical activity level. To ensure tolerance to the drug, you will be instructed to start with a very low dose in the first 4 weeks and increase gradually every 4 weeks until reaching a full dose. A trained health professional will teach you step-by-step on the injection technique, how to adjust the dose and how to store the drug. For safety purpose, you will be monitored closely by us at each study visit.

Study visits (remote visits): The majority of the study visits will happen remotely. A member of the study team will contact you at an agreed mutually convenient time. Remote visits will take place every week for the first 2 weeks, every two weeks for the following 14 weeks, then monthly until the end of the trial. Remote visits will be either a phone call or video call and will last approximately 15 to 30 minutes. You will be asked to let us know your weight, the dates you took your injections and if you experienced any side effects. You will have the opportunity to ask questions and be given nutrition and physical activity advice.

Study visits (site visits): You will be asked to attend in person for five additional appointments during the trial, after the baseline visit (visit 2). The purpose of the assessments performed during these visits will be to ensure your safety and collect data on your health. These visits will last approximately 45 minutes. The following assessments will be done during these visits:

- You will undergo a physical examination that involves measurement of your blood pressure, heart rate, weight and BIA scan.
- A blood sample will be taken to measure your kidney, liver function and markers of inflammation.
- Your drug diary will be reviewed and you will be asked if you experienced side effects.
- You will be given advice on nutrition and exercise.

You will be given 4 questionnaires to complete, which will contain questions about appetite, physical activity and quality of life. At your final visit, which will be at the end of the treatment period, in addition to those assessment you will also have an ECG and if you are a female of childbearing age you will be asked to provide a urine sample for a pregnancy test.

Wash out period and end of trial assessment: After you receive your final dose of treatment, you will remain in the trial for a further 6 weeks. The study team will contact you for 2 remote visits during this time. These will last approximately 15 minutes and will ask you for your weight and any side effects that you may have experienced.

One of the treatment groups in this study will get a placebo instead of Semaglutide. A placebo is a dummy treatment which looks like semaglutide but contains no active ingredient. This is a double blinded study, neither you nor your doctor will know which treatment group you are in. However, your doctor will be able to find out which treatment group you are in if required (e.g., for a medical emergency).

Visit Schedule Plan

Visit	*Visit Timing*	*What will happen (list all assessments done at the visit)*	*How much time will this take?*
Screening visit		✓ Study explanation ✓ Physical examination (blood pressure, heart rate, BIA, height and weight) ✓ Medical History ✓ Blood test ✓ Urine test (this will include a pregnancy test if you are female and of child bearing potential) ✓ Review of adequate contraceptive use ✓ Review of any medication you are already taking (concomitant medications)	*1 hour*
Baseline Visit	Day 1	✓ Physical examination (blood pressure, heart rate, BIA, ECG, height and weight) ✓ Collection of sociodemographic data ✓ Blood pregnancy test if you are female and of child bearing potential ✓ Fasted meal test: A baseline blood sample will be obtained via cannula or venepuncutre. A liquid meal drink over a 10-minute period. At 30 minutes post-meal another blood sample will be obtained via cannula or venepuncture.	*3 hours*

		✓ Questionnaires (questions regarding appetite, physical activity and quality of life) ✓ Injection training and lifestyle advice (nutrition and exercise) ✓ Provided with a drug diary, scales, trial medicine, injection needles and sharps bin.	
Follow-up remote visits	Every 1-2 weeks for the first 14 weeks: Weeks 1, 2, 4, 8, 10, 12. Then once per month until the end of trial: Weeks 16, 20, 24, 28, 36, 40, 44, 48, 56, 60, 64.	✓ Phone call or video call to discuss: - Weight - Concomitant medication use - The dates you took your injections - Any side effects - Questions you may have - Nutritional and physical activity advice.	*15-30 minutes*
Follow up site visits	There will be 5 in person follow-up visits: ✓ Week 6 ✓ Week 14 ✓ Week 32 ✓ Week 52 ✓ Week 68 (end of treatment)	✓ Physical examination (blood pressure, heart rate, weight and BIA scan) ✓ A blood test ✓ Review of drug diary and any side effects experienced ✓ Given nutrition and physical activity advice ✓ Questionnaires about appetite, physical activity and quality of life ✓ Review of concomitant medications ✓ End of treatment visit – in addition to above assessments, ECG and urine test (if you are a female of childbearing age)	*45 minutes*
End of trial assessment (2 remote visits during 6 week wash out period)	Week 70 and 74	✓ Phone call or video call to discuss: - Weight - Concomitant medications - Any side effects experienced	*15 minutes*

5. What will I have to do?

If enrolled in the study, we will expect you to attend all scheduled study visits, either in person or remotely, and perform the tests and assessment as listed above, accordingly to the study protocol.

Importantly, you will be asked to take the study treatment by weekly injections: you will be given training on how to perform the injection. Information about the study drug, semaglutide and placebo, are provided under section 1 'What's the purpose of the study?', section 7 'What are the possible disadvantages and risks in taking part?' and below.

After the baseline visits, you will have to take the injection once every week on the same day of the week. You will also be advised to follow a specific diet and to increase your physical activity level. To ensure tolerance to the drug, you will be instructed to start with a very low dose in the first 4 weeks and increase gradually every 4 weeks until reaching a full dose. A trained health professional will teach you step-by-step on the injection technique, how to adjust the dose and how to store the drug. For safety purposes, you will be monitored closely by us at each study visit. There will be a total of 26 study visits, 7 of these will be in person at UCLH (details of the location will be provided before each appointment) and 19 will be done remotely, via phone or video call. You will be asked to check your weight at home before every remote visit using the scale we provide and fill in a drug diary every week at the time you complete your injection. Should you be already taking part in other drug studies you may not be eligible to take part in this study: this will be reviewed during the screening visit.

6. What are the alternatives for diagnosis or treatment?

Currently, there are no available drug treatments for people with poor weight loss after bariatric surgery and the only treatment option is revision surgery, which has a high risk of complications and can be difficult to access.

7. What are the possible disadvantages and risks of taking part?

Possible disadvantages and risks are related to the study assessments, procedures and questionnaires you will have to undergo when taking part in the trial. However, these would be considered minor risks/disadvantages, as explained below.

As part of the trial visits, you will undergo physical examinations and blood sampling. During the baseline visits (Visit 2) for the purpose of the meal test you will choose between having a cannula inserted or venepuncture (a standard blood test). During the cannula insertion or venepuncture you may feel a little discomfort/pain and some bruising or bleeding can occur at the site where the needle goes in. Although extremely rare, there is a very slight possibility that the insertion point for the cannula or venepuncture might become infected. These procedures will be performed by trained healthcare professionals. When the ECG is being recorded, your skin may react to the patches used to attach the leads. When injecting the drug, you may feel either nothing or a little sting at the injection site. A trained health professional will teach you step-by-step on a correct injection technique. If, as a result of taking part in the study or answering the questionnaires, you become concerned about your feelings you can talk to your GP. You can also raise this with the study investigators.

Your participation in the study could affect any insurance you have (e.g., travel insurance, protection insurance (life insurance, income protection, critical illness cover) and private medical insurance) and you may need to seek advice on these issues if you think you could be affected.

Side effects of Semaglutide:

Semaglutide is very similar to the body's hormone GLP-1. Semaglutide is likely to make you feel less hungry. Like with all medications, there are side effects than can occur with semaglutide and these will be fully explained to you before you decide to take part in the study. If side effects happen, these will be treated as/if required. We will provide you with a contact card with details of persons to contact should you have any problem while on the treatment. You should carry this with you at all times. If you are admitted to a hospital or have to see your GP in between hospital visits, please remember to show them the contact card in case they need to speak to the study doctor. In addition, we will monitor you closely throughout the study period and specifically ask you at each study visit to let us know if you experience any side effects. It is unlikely that you will experience all of the side effects listed below, or even many of them, but we cannot predict which ones you will experience, or how serious they may be. These are side effects we know about from other studies with semaglutide that have been undertaken in over 5000 people with overweight or obesity.

Very common side effects (may affect more than 1 in 10 people):

- Feeling sick (nausea) or vomiting
- Constipation
- Abdominal pain
- Diarrhoea (loose stools) or constipation
- Fatigue
- Headache

These symptoms are mild in most people, usually happen at the start of treatment and do not last for a very long time. To reduce the risk of experiencing these side effects the dose of semaglutide is slowly increased over 16 weeks.

Common side effects (May affect more than 1 in 100 but fewer than 1 in 10):

- Low appetite, feeling bloated, stomach discomfort
- Heartburn
- Burping
- Skin irritation where the injection is given
- Hair loss
- Dry mouth
- Gallstones
- Headache
- Fatigue
- Dizziness
- Flatulence

Uncommon side effects (may affect up to 1 in 100 people)

- Fast heart rate (pulse)
- Inflamed pancreas (pancreatitis).

Other rare side effects: Serious allergic reactions.

Placebo does not contain any active ingredients; therefore, no side effects are expected if you receive this treatment.

8. Pregnancy and Contraception Information

For female participants: You must not take part in this study if you are pregnant, breast-feeding, or planning a pregnancy. This is because we do not know if the study medicine can affect you or your baby. Semaglutide can stay in your body for some weeks after you stop taking it. Therefore, you should avoid becoming pregnant and you should continue to use contraception for at least 2 months after you stop taking the study medicine. If you are female and able to get pregnant, you will be asked to take a pregnancy test before taking part to exclude the possibility of pregnancy. You will also only be able to take part if you use a highly effective method of contraception during the course of the trial, such as surgical sterilisation, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy, or total abstinence from intercourse with male partners.

If you become pregnant during the trial, stop taking the study medicine and tell the study staff straight away to discuss whether it is still safe for you to continue being on the study. With your consent, we will like to monitor the pregnancy and, therefore, request information on the pregnancy and child's birth that is relevant to your participation on the study. If this relevant information needs to be reported to the sponsor, study drug manufacturer, ethics committee or UK regulatory body for medicines, the information will be anonymised so that neither the new born child nor you can be identified.

For male participants with female partners: Male participants with pregnant partners, or partners of child-bearing potential should use barrier methods of contraception for the duration of the trial until 2 months after treatment discontinuation. If your partner becomes pregnant during the study, or within 2 months of you stopping treatment, you must tell your doctor immediately. Please share this information with your partner if there is a possibility that your partner is pregnant or that they might become pregnant during your time on this study, we will give your partner information on why we may wish to follow up on their pregnancy and seek their specific consent to access their medical notes.

9. What are the possible benefits of taking part?

We do not know whether you will benefit personally from taking part in this study, but the knowledge gained from this study will inform future treatment and potentially lead to improved treatment for patients with a suboptimal weight loss response after bariatric surgery in the future. You may benefit from the contact with the healthcare professionals in the study and from taking the study medicine; this could lead to weight loss and improvements in your health.

10. What happens when the clinical study stops?

We will not be able to provide semaglutide at the end of your participation in the trial. Although semaglutide is a licensed drug, your GP may not be able to prescribe this for you as it is not currently licensed for use for poor weight loss after bariatric surgery. National Institute for Health and Care Excellence (NICE) are currently deciding which people with overweight /obesity will be able to receive semaglutide, paid for by the NHS. More details about if and when semaglutide might become available to be prescribed for you by your clinical care teams is likely to become available during the study. You will be able to discuss this with the study team as more information becomes

available. At the end of the trial the clinical bariatric team will continue to support you to manage your weight.

At the end of the trial, we will analyse the data and publish the results in medical journals, and present at scientific conferences. At this stage, we will also be able to let you know what trial arm you were in and whether you received semaglutide or the placebo. If you wish, a copy of the reports on the study findings can be requested from the Chief Investigator, Dr Janine Makaronidis, at the addresses given at the end of this information sheet. Should the study be stopped prematurely for any reason, we will tell you why and arrange for your continuing care.

11. What if there is a problem?

Any complaint about the way you have been dealt with during the clinical study or any possible harm you might suffer will be addressed. The detailed information concerning this is given in Part 2 of this information sheet – Supporting Information. If you have any concerns or complaints, you should contact your study doctor in the first instance.

12. Will my taking part in the study be kept confidential?

Yes. We will follow ethical and legal practices and all information about you will be handled in confidence. The details are included in Part 2 – Supporting Information.

13. Expenses and payments

Any reasonable travel costs incurred by you in attending the study visits will be reimbursed on production of valid receipts.

14. Contact Details

Your Doctor
Name: Dr Janine Makaronidis Email: j.makaronidis@nhs.net

Research Assistant and Trial Contact
Name: Ms Chloe Firman Email: chloe.firman.19@ucl.ac.uk

This completes Part 1 of the Information Sheet.

If the information in Part 1 has interested you and you are considering participation, please read the additional information in Part 2 before making any decision.

Part 2 - Supporting Information

1. What if relevant new information becomes available?

Sometimes during a clinical trial, new information about the drug becomes available. If this happens, we will tell you about it and discuss with you whether you want to or should continue your participation in this study. If you decide not to carry on, we will make arrangements for your care to continue. If you decide to continue in the study, you might be asked to sign an updated consent form. Also, on receiving new information, we might consider it to be in your best interest to withdraw from the study. If so, we will explain the reasons and arrange for your care to continue.

2. What will happen if I don't want to carry on with the study?

Your participation in the trial is entirely voluntary and you will be free to withdraw from the study at any time and without giving a reason. A decision to withdraw will not affect the current or future care you receive. If you withdraw from the study, we will destroy all your identifiable information, but we will need to use and analyse the pseudonymised data collected up to the point of your withdrawal. You can also decide to discontinue the treatment and keep in contact with us to let us know your progress by continuing with the scheduled visit programme. You will be provided with a withdrawal form where you will be able to express your preference. In any case, pseudonymized (coded) information collected up to the point of your withdrawal will still be used in the analysis. Any stored blood or tissue samples that can still be identified as yours will be destroyed if you wish.

3. What if there is a problem?

If you have any problem during the study, or would like to discuss any aspect of the study, you can contact any of the research investigators. You can find their contact detail on the last page of this information sheet. Every care will be taken in the course of this clinical trial. You can also speak to the Patient Advice and Liaison Service (PALS) at UCLH (by telephone (main hospital: 020 3447 3042); NHNN: 02034483237) or email: uclh.pals@nhs.net), Ground Floor Atrium, University College Hospital, 235 Euston Road, London NW1 2BU.

However, in the unlikely event that you are injured by taking part, compensation may be available through the University College London (UCL) insurance scheme. If you suspect that the injury is the result of the Sponsor's (University College London) or the hospital's negligence then you may be able to claim compensation. After discussing with your research doctor, please make the claim in writing to the Chief Investigator for this trial:

Dr Janine Makaronidis,
Centre for Obesity Research,
Rayne Building,
5 University Street,
London, WC1E 6JF.

The Chief Investigator will then pass the claim to the Sponsor's Insurers, via the Sponsor's office.

However, if you remain unhappy or have a complaint about any aspect of this study and wish to speak to someone independent of the research team/hospital, please contact the Head of Research Governance and Compliance, UCL/UCLH Joint Research Office, University College London, Gower Street, London WC1E 6BT email: research-incidents@ucl.ac.uk.

Regardless of this, if you wish to complain, or have any concerns about any aspect of the way you have been approached or treated by members of staff or about any side effects (adverse events) you may have experienced due to your participation in the clinical trial, the normal National Health Service complaints mechanisms are available to you. You could also write or get in touch with the Complaints Manager, UCL hospitals. Please quote the study IRAS number at the bottom of this information sheet. Please ask your study doctor if you would like more information on this. Details can also be obtained from the NHS website and the Department of Health website: http://www.dh.gov.uk. In case you feel you would benefit from some emotional support, you can contact the Samaritans charity on 116 123, their helpline is open 24 hours per day. The CALM (Campaign against living miserably) charity also have a helpline open from 5pm to midnight every day on 0800 58 58 58 or a web chat (https://www.thecalmzone.net).

4. How will we use information about you?

Data Protection Information

UCL is the sponsor for this study based in the United Kingdom. The sponsor is the organisation responsible for ensuring that the study is carried out correctly. We will be using your personal data (such as contact details [name, telephone number(s), email address, NHS/hospital number], demographics [age, gender, marital status, ethnicity, education, occupation]) from your medical records in order to undertake this study.

UCL will act as the data controller for this study. This means that they are responsible for looking after your information and using it properly. UCL will keep this information about you for 25 years after the study has finished. The UCL Data Protection Office provides oversight of UCL activities involving the processing of personal data and can be contacted at data-protection@ucl.ac.uk. Further information on how UCL uses your information can be found on our general research privacy notice here https://www.ucl.ac.uk/legal-services/privacy.

We collect personal data directly from you, or your GP and/or hospital team if needed, for the purposes of carrying out this research study. We use your name, NHS number and contact details to contact you about the research study and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. We only share your personal data in limited circumstances, with your GP, as set out in this information sheet, and with individuals from regulatory organisations where they need to look at your medical and research records to check the accuracy of the research study. The only people in UCL who will have access to information that identifies you will be people who need to contact you as part of the study or audit the data collection process. The people who analyse the study data will not be able to identify you and will not be able to find out your name, NHS number or contact details. Information relating to any serious side effects you may experience and pregnancies will be sent by us to Novo Nordisk, who are manufacturing and providing semaglutide for the study, so they can monitor the safety of their drug. Any information sent will be coded and they will not be able to identify you. They will keep all information about you safe and secure. We will keep all information about you safe and secure. The information collected about you may also be shown to authorised people from the UK Regulatory Authority (the Medicines and Healthcare Products Regulatory Authority); this is to ensure that the study is carried out to the highest possible scientific standards Once we have finished the study, we will keep some of the data so we can check the results. The final study

reports will contain anonymised data only and will not contain any identifiable data or personal information.

Your personal data will be processed for the purposes outlined in this information sheet. The legal basis to process your personal data will be:

- to undertake the research study, on the basis of performance of a task carried out in the public interest and processing your special categories of personal data (e.g., health information) for research purposes.
- where required to make disclosures to your GP further to the results of any study test/questionnaire, on the basis of performance of a task carried out in the public interest, compliance with a legal obligation and processing your special categories of personal data (e.g., health information) for public health purposes.
- to contact you about participating in further research studies, only where you have provided consent on the consent form. You have the right to withdraw your consent to be contacted about future studies at any time, using the details set out at the end of this section.

Your personal data will be processed only for so long as it is required for the research project. We will pseudonymise the personal data as soon as registered on the study database and endeavour to minimise the processing of personal data, wherever possible, to safeguard your privacy. In the event of any future loss of capacity to make decisions relating to your ongoing participation in this study, you will automatically be withdrawn from the study. The information already collected up to that point, may continue to be used confidentially in connection with this study and future research, if applicable.

In line with the regulations, at the end of the study your data will be securely archived for a minimum of 5 years.

Under data protection law, you have individual rights in relation to the personal data we hold about you. For the purposes of research where such individual rights would seriously impair research outcomes, such rights may be limited. In fact, as we need to manage your records in specific ways for the research to be reliable, we will not be able to let you see or change the data we hold about you. If you would like to exercise a right under data protection law or find out more about how we use your information, please contact data-protection@ucl.ac.uk.
You can find out more about how we use your information:

- at www.hra.nhs.uk/information-about-patients/
- by asking one of the research team
- on our website https://www.ucl.ac.uk/legal-services/privacy/participants-health-and-care-research-privacy-notice
- by sending us an email and/or ringing us: our contact details are on the next page.

If you remain unsatisfied, you may wish to contact the Information Commissioner's Office (ICO) (https://ico.org.uk/concerns/handling/).

5. Will my GP be informed of my involvement?

With your permission, your GP will be notified that you are taking part in this study. If the study investigators became concerned about your well-being or about the implications of what you tell us for someone else's well-being we would need to inform your GP or other professionals. We

would, of course, discuss this with you first. In addition, should your blood test results show any anomaly, we will let your GP and/or the Bariatric Team clinicians know who will be able to make necessary arrangements for your best care. You will be asked to agree to this when signing the consent form.

6. What will happen to any samples I give?

As part of this trial, we will collect new blood samples from you during the face-to-face visits, as detailed above. These blood samples will be stored and analysed at UCLH and the Centre for Obesity Research, University College London (UCL). Samples will be anonymised, this means they will not be identifiable. The samples will be identified only by your study number and will not be directly marked with your name. The samples will only be used for the study described above, however, with your consent, any remaining blood samples you provided for the study may be retained after the end of the study for future research. Only researchers involved in this study will have access to the blood samples. At the end of the study, or future research, your samples will be disposed of in accordance with the Human Tissue Act 2004. If you choose to withdraw from the study, any stored blood or tissue samples that can still be identified as yours will be destroyed if you wish. If you are a female of childbearing age, your urine sample will be used to check whether you might be pregnant at the end of treatment and discarded immediately after the result of the test is available. We will not store or use your urine sample in any other additional test.

7. What will happen to the results of the clinical trial?

The results of the study will be available after it finishes and will usually be published in a medical journal or presented at a scientific conference. The data will be anonymised and none of the participants involved in this study will be identified in any report or publication. We will be happy to make the results of the study available to you. You can request a lay summary of the study results by ticking the corresponding box in the consent form.

8. Who is organising and funding the research?

This research study is being organised by the Centre for Obesity Research, University College London (UCL). The Chief Investigator is Dr Janine Makaronidis who has a vast experience in clinical research studies. This study is being sponsored by University College London (UCL) and being funded by the University College London Hospital Biomedical Research Centre (UCLH BRC). The study drug, semaglutide and the placebo have been funded and provided by the manufacturer, Novo Nordisk. All of these organisations and Novo Nordisk (manufacturer of semaglutide and placebo for this study) have reviewed the proposed study.

9. How have patients and the public been involved in this study?

In designing and planning this study, we have taken into account patient/ public opinions who reviewed the study protocol, which included the frequency of participant visits and the tests that we will carry out.

10. Who has reviewed the study?

All research in the NHS is looked at by independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by the London - Surrey Borders Research Ethics Committee as well as the Health research Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA)

11. Further information and contact details

You are encouraged to ask any questions you wish, before, during or after your treatment. If you have any questions about the study, please speak to your study nurse or doctor, who will be able to provide you with up to date information about the drug(s)/procedure(s) involved. If you wish to read the research on which this study is based, please ask your study nurse or doctor. If you require any further information or have any concerns while taking part in the study please contact one of the following people:

Your Doctor
Name: Dr Janine Makaronidis Email: j.makaronidis@ucl.ac.uk

Research Assistant and Trial Contact
Name: Ms Chloe Firman Email: chloe.firman.19@ucl.ac.uk

If you decide you would like to take part then please read and sign the consent form. You will be given a copy of this information sheet and the consent form to keep. A copy of the consent form will be filed in your patient notes, one will be filed with the study records and one may be sent to the Research Sponsor.

You can have more time to think this over if you are at all unsure.

Thank you for taking the time to read this information sheet and to consider this study.

Chief Investigator
Dr Janine Makaronidis
j.makaronidis@ucl.ac.uk

Research Assistant and Trial Contact
Ms Chloe Firman
Chloe.firman.19@ucl.ac.uk

Centre for Obesity Research
Division of Medicine
University College London
Rayne Building
5 University Street
London WC1E 6JF

Sponsor Protocol Number: 142522 Centre Number: 01
Patient Identification Number:

CONSENT FORM

Title of Project: BARI-STEP Trial: A double-blinded, randomised, placebo-controlled trial of semaglutide 2.4 mg in patients with poor weight-loss following bariatric surgery.

Chief Investigator: Dr Janine Makaronidis

Thank you for considering taking part in this project. If you have any questions arising from the Information Sheet or explanation already given to you, please ask the research team before you decide whether to join in, contact details are on the top of this page.

DECLARATION
I understand that by adding my initials in each box below, I am consenting to this element of the study. I understand that it will be assumed that boxes not initialed mean that I DO NOT consent to that part of the study. I understand that by not giving consent for any one element (excluding the optional ones) I may be deemed ineligible for the study.

Please initial each box to indicate your agreement:

1. I confirm that I have read and understand the information sheet V4.1, 24-10-2023, for the above study. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.	
2. I confirm that I have been informed about any risks that may result from this study and that I have had sufficient time to consider whether or not to take part.	
3. I understand that my participation is voluntary and that I am free to withdraw at any time without giving any reason, without my medical care or legal rights being affected.	☐

4. I agree for appropriately qualified staff to undertake the assessments as outlined in the participant information sheet V4.1, 24-10-2023.	☐
5. I understand that relevant sections of my medical notes and data collected during the study, may be looked at by individuals from the sponsor of the trial (University College London) and responsible persons authorised by the sponsor, from regulatory authorities or from the NHS Trust, where it is relevant to my taking part in this research. I give permission for these individuals to have access to my records. I understand that such information will be handled appropriately and confidentially.	☐
6. I agree to comply with the requirements of the study as outlined to me to the best of my abilities. I shall inform the investigators and/or my doctor immediately if I have any concerns and/or experience any unexpected symptoms.	☐
7. I give permission for a researcher to contact me, for the purposes of arranging study visits, ensuring study diaries have been completed before a scheduled trial visit, to offer support and for the purpose of carrying out the remote study visits.	☐
8. I give permission for these blood samples to be stored and analysed at the University sites.	☐
9. I agree that in the event that I lose the capacity to make decisions relating to my ongoing participation in this study, I will automatically be withdrawn from the study. The information already collected up to that point may continue to be used confidentially in connection with this study and future research, if applicable, as described in the Participant Information Sheet V4.1, 24-10-2023.	☐
10. I acknowledge that UCL will handle my personal data for the purposes of this research study and I have been provided with information about how UCL handles personal data, as described in the Participant Information Sheet V4.1, 24-10-2023.	☐
11. I give permission for my anonymised data to be used in future publications related to this study and to be stored anonymously and securely for up to 25 years.	☐
12. I agree to my GP being informed of my participation in the study.	☐

13. If I or my partner becomes pregnant whilst I am on this study, I understand that my doctor will inform the treating obstetrician of my involvement in this study and that the obstetrician may be requested to provide relevant information regarding the pregnancy and/ or birth. I understand that this may involve requesting access to my medical records and that anonymised information relating to the pregnancy or birth may be reported to the sponsor, ethics committee or regulatory authorities. I give permission for these individuals to have access to my medical records.	☐
14. I voluntarily agree to take part in the above study.	☐
OPTIONAL	
15. Please send me a summary of the results.	☐
16. I understand that my blood samples are viewed as a gift, and that any remaining blood sample I provided for the study may be retained at the end of the study for future research.	☐
17. I give permission for my personal information to be retained and used to contact me for the purpose of future research.	☐

Name of Participant	Date	Signature

I confirm that I have explained the study to the above participant and have answered questions honestly and fully.

Name of Person taking consent	Date	Signature

Comments or concerns during the study

If you have any comments or concerns, you may discuss these with the investigators. If you wish to go further and complain about any aspect of the way you have been approached or treated during the course of the study, you should write or get in touch with the Complaints Manager, UCL Hospitals. Please quote the study number on the front page of this consent form.

When completed: 1 for participant; 1 (original) for researcher site file; 1 to be kept in medical notes.

Sponsor Protocol Number: 142522 Centre Number: 01
Patient Identification Number:

OPTIONAL CONSENT – For the Future Use of Research Samples

Title of Project: **BARI-STEP Trial: A double-blinded, randomised, placebo-controlled trial of semaglutide 2.4 mg in patients with poor weight-loss following bariatric surgery.**

Chief Investigator: Dr Janine Makaronidis

We would like to ask for consent for any remaining blood samples you provided for the Study to be retained after the end of the study.

Future use of your blood samples is optional and is not required in order to participate in the study. If you do not consent to future use of blood samples, please simply leave the section below blank.

Please initial box to indicate your agreement:

1.	I agree that any remaining blood samples I provided for the Study may be retained after the end of the study for future research.	☐
2.	I understand that the use of my blood samples will be restricted to ethically approved studies.	☐
3.	I understand that my samples may be stored and tested at laboratories located in the UK.	☐
4.	I understand that my samples will be coded and all personal identifiers will be removed, but the results of tests on my samples may be linked to clinical data about me collected during the course of treatment on this study. I understand that my identity will remain anonymous.	☐

_____	_____	_____
Name of Participant	Date	Signature

_____	_____	_____
Name of Person taking consent	Date	Signature

When completed, 1 for patient; 1 (original) for researcher site file; 1 to be kept in medical notes.